QuidelOrtho Corporation (QDEL) 10-Year Financial Performance & Capital Metrics

QDEL • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

AboutQuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.Show more

Revenue $2.78B -7.2%
EBITDA -$1.51B -352.8%
Net Income -$2.05B -20216.8%
EPS (Diluted) -30.54 -20260.0%
Gross Margin 46.23% -7.3%
EBITDA Margin -54.17% -372.3%
Operating Margin -70.46% -1618.6%
Net Margin -73.74% -21786.6%
ROE -51.36% -25176.4%
ROIC -22.51% -1717.1%
Debt/Equity 0.90 +72.0%
Interest Coverage -10.41 -1439.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)
✓Strong 5Y sales CAGR of 39.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y31.31%

5Y39.07%

3Y17.89%

TTM-3.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM36.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM39%

ROCE

10Y Avg15.74%

5Y Avg26.03%

3Y Avg-3.69%

Latest-29.81%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	196.13M	191.6M	277.74M	522.28M	534.89M	1.66B	1.7B	3.27B	3B	2.78B
Revenue Growth %	0.07%	-0.02%	0.45%	0.88%	0.02%	2.11%	0.02%	0.92%	-0.08%	-0.07%
Cost of Goods Sold+	71.69M	73.41M	121.6M	206.57M	214.09M	312.81M	420.3M	1.33B	1.5B	1.5B
COGS % of Revenue	0.37%	0.38%	0.44%	0.4%	0.4%	0.19%	0.25%	0.41%	0.5%	0.54%
Gross Profit+	124.44M	118.19M	156.14M	315.71M	320.81M	1.35B	1.28B	1.94B	1.49B	1.29B
Gross Margin %	0.63%	0.62%	0.56%	0.6%	0.6%	0.81%	0.75%	0.59%	0.5%	0.46%
Gross Profit Growth %	0.15%	-0.05%	0.32%	1.02%	0.02%	3.2%	-0.05%	0.51%	-0.23%	-0.14%
Operating Expenses+	121.7M	122.63M	130.08M	205.59M	228.09M	288.53M	372.3M	1.09B	1.36B	3.25B
OpEx % of Revenue	0.62%	0.64%	0.47%	0.39%	0.43%	0.17%	0.22%	0.33%	0.45%	1.17%
Selling, General & Admin	77.33M	74.88M	96.44M	153.94M	163.87M	200.54M	239.6M	621M	763.2M	766.8M
SG&A % of Revenue	0.39%	0.39%	0.35%	0.29%	0.31%	0.12%	0.14%	0.19%	0.25%	0.28%
Research & Development	35.51M	38.67M	33.64M	51.65M	52.55M	84.29M	95.7M	187.9M	246.8M	218.7M
R&D % of Revenue	0.18%	0.2%	0.12%	0.1%	0.1%	0.05%	0.06%	0.06%	0.08%	0.08%
Other Operating Expenses	8.86M	9.07M	0	0	11.67M	3.69M	37M	283.6M	345.3M	2.26B
Operating Income+	2.74M	-4.44M	9.55M	95.93M	92.72M	1.06B	906M	843.7M	139.1M	-1.96B
Operating Margin %	0.01%	-0.02%	0.03%	0.18%	0.17%	0.64%	0.53%	0.26%	0.05%	-0.7%
Operating Income Growth %	1.3%	-2.62%	3.15%	9.04%	-0.03%	10.44%	-0.15%	-0.07%	-0.84%	-15.1%
EBITDA+	11.59M	27.43M	40.31M	142.19M	140.54M	1.11B	958.7M	1.13B	596.3M	-1.51B
EBITDA Margin %	0.06%	0.14%	0.15%	0.27%	0.26%	0.67%	0.56%	0.35%	0.2%	-0.54%
EBITDA Growth %	31.51%	1.37%	0.47%	2.53%	-0.01%	6.89%	-0.14%	0.18%	-0.47%	-3.53%
D&A (Non-Cash Add-back)	8.86M	31.87M	30.76M	46.27M	47.83M	49.09M	52.7M	283.6M	457.2M	453.4M
EBIT	2.74M	-4.02M	9.55M	87.67M	91.97M	1.05B	900.6M	810.4M	149.8M	-1.94B
Net Interest Income+	-12.04M	-12.18M	-17.59M	-24.28M	-14.79M	-1.26M	-400K	-73.2M	-176.7M	-188.9M
Interest Income	0	0	0	0	0	0	300K	1.3M	2.2M	0
Interest Expense	12.04M	12.18M	17.59M	24.28M	14.79M	1.26M	700K	74.5M	178.9M	188.3M
Other Income/Expense	-12.04M	-11.76M	-17.59M	-32.55M	-15.54M	-20.01M	-5.7M	-107.8M	-168.2M	-170.6M
Pretax Income+	-9.3M	-16.2M	-8.04M	63.38M	77.18M	1.04B	900.3M	735.9M	-29.1M	-2.13B
Pretax Margin %	-0.05%	-0.08%	-0.03%	0.12%	0.14%	0.63%	0.53%	0.23%	-0.01%	-0.77%
Income Tax+	-3.22M	-2.39M	129K	-10.8M	4.26M	230.03M	196.1M	187.2M	-19M	-79.5M
Effective Tax Rate %	0.65%	0.85%	1.02%	1.17%	0.94%	0.78%	0.78%	0.75%	0.35%	0.96%
Net Income+	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.2M	548.7M	-10.1M	-2.05B
Net Margin %	-0.03%	-0.07%	-0.03%	0.14%	0.14%	0.49%	0.41%	0.17%	-0%	-0.74%
Net Income Growth %	0.14%	-1.27%	0.41%	10.09%	-0.02%	10.11%	-0.13%	-0.22%	-1.02%	-202.17%
Net Income (Continuing)	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.2M	548.7M	-10.1M	-2.05B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.18	-0.42	-0.24	1.74	1.73	18.60	16.43	9.56	-0.15	-30.54
EPS Growth %	0.14%	-1.33%	0.43%	8.25%	-0.01%	9.75%	-0.12%	-0.42%	-1.02%	-202.6%
EPS (Basic)	-0.18	-0.42	-0.24	1.74	1.78	19.24	16.74	9.66	-0.15	-30.54
Diluted Shares Outstanding	34.1M	32.71M	33.73M	42.55M	43.11M	43.59M	42.87M	57.4M	66.8M	67.2M
Basic Shares Outstanding	33.77M	32.71M	33.73M	42.55M	40.86M	42.12M	42.08M	56.8M	66.8M	67.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	240.66M	225.39M	331.23M	193.4M	222.23M	1.14B	1.44B	1.58B	1.31B	1.22B
Cash & Short-Term Investments	191.47M	169.51M	36.09M	43.7M	52.77M	489.94M	828.5M	345M	167.3M	98.3M
Cash Only	191.47M	169.51M	36.09M	43.7M	52.77M	489.94M	802.8M	292.9M	118.9M	98.3M
Short-Term Investments	0	0	0	0	0	0	25.7M	52.1M	48.4M	0
Accounts Receivable	18.4M	24.99M	78.36M	76.89M	102.35M	529.17M	393.8M	586.4M	488.4M	451.3M
Days Sales Outstanding	34.24	47.61	102.98	53.73	69.84	116.24	84.62	65.53	59.47	59.19
Inventory	26.39M	26.05M	67.08M	67.38M	58.09M	113.8M	198.8M	524.1M	577.8M	533.7M
Days Inventory Outstanding	134.35	129.49	201.34	119.05	99.03	132.78	172.64	143.85	140.28	130.18
Other Current Assets	63K	0	146.81M	928K	4.45M	2.16M	4.6M	22.9M	10M	58.3M
Total Non-Current Assets+	165.84M	162.86M	604.02M	612.97M	688.64M	728.76M	990.1M	7.28B	7.25B	5.2B
Property, Plant & Equipment	52.55M	50.86M	61.59M	73.9M	171.88M	211.03M	476.8M	1.52B	1.61B	1.55B
Fixed Asset Turnover	3.73x	3.77x	4.51x	7.07x	3.11x	7.87x	3.56x	2.15x	1.86x	1.80x
Goodwill	80.73M	83.83M	337.03M	337.02M	337.02M	337.03M	337M	2.48B	2.49B	649.5M
Intangible Assets	31.83M	27.64M	203.83M	175.03M	148.11M	122.43M	98.7M	3.12B	2.93B	2.74B
Long-Term Investments	0	0	0	0	0	0	37.9M	21M	7.4M	21.7M
Other Non-Current Assets	731K	525K	1.58M	4.83M	7.13M	13.51M	19.6M	122.7M	179.6M	249M
Total Assets+	406.5M	388.25M	935.25M	806.37M	910.87M	1.87B	2.43B	8.86B	8.56B	6.42B
Asset Turnover	0.48x	0.49x	0.30x	0.65x	0.59x	0.89x	0.70x	0.37x	0.35x	0.43x
Asset Growth %	-0.09%	-0.04%	1.41%	-0.14%	0.13%	1.05%	0.3%	2.64%	-0.03%	-0.25%
Total Current Liabilities+	30.83M	33.61M	128.35M	159.74M	125.89M	336.96M	323.5M	1.01B	833.8M	998.8M
Accounts Payable	8.68M	16.05M	27.28M	25.17M	26.7M	86.32M	101.5M	283.3M	294.8M	246M
Days Payables Outstanding	44.17	79.78	81.88	44.48	45.52	100.72	88.15	77.76	71.57	60
Short-Term Debt	0	0	20.18M	54.38M	12.66M	0	300K	207.5M	139.8M	341.8M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	336K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	8.08M	7.6M	64.52M	59.01M	62.49M	74.39M	65.5M	156.4M	127.8M	96.8M
Current Ratio	7.81x	6.71x	2.58x	1.21x	1.77x	3.39x	4.45x	1.56x	1.57x	1.22x
Quick Ratio	6.95x	5.93x	2.06x	0.79x	1.30x	3.05x	3.84x	1.04x	0.88x	0.69x
Cash Conversion Cycle	124.42	97.31	222.44	128.31	123.35	148.3	169.12	131.63	128.17	129.37
Total Non-Current Liabilities+	157M	154.01M	579.8M	221.05M	225.16M	201.5M	177.5M	2.91B	2.72B	2.44B
Long-Term Debt	143.3M	144.34M	377.26M	53.19M	0	0	400K	2.43B	2.27B	2.14B
Capital Lease Obligations	4.03M	3.98M	0	0	93.23M	100.71M	128.6M	186.4M	172.8M	167.2M
Deferred Tax Liabilities	1.97M	58K	430K	9.81M	30.02M	38.33M	0	213.2M	192.2M	76.5M
Other Non-Current Liabilities	7.7M	5.63M	202.11M	167.86M	131.93M	100.79M	48.5M	74.4M	83.6M	38M
Total Liabilities	187.83M	187.62M	708.15M	380.79M	351.05M	538.46M	501M	3.92B	3.56B	3.44B
Total Debt+	147.91M	148.42M	397.45M	107.57M	112.3M	108.5M	139.3M	2.85B	2.61B	2.68B
Net Debt	-43.56M	-21.09M	361.36M	63.87M	59.52M	-381.44M	-663.5M	2.56B	2.5B	2.58B
Debt / Equity	0.68x	0.74x	1.75x	0.25x	0.20x	0.08x	0.07x	0.58x	0.52x	0.90x
Debt / EBITDA	12.76x	5.41x	9.86x	0.76x	0.80x	0.10x	0.15x	2.53x	4.38x	-
Net Debt / EBITDA	-3.76x	-0.77x	8.96x	0.45x	0.42x	-0.34x	-0.69x	2.27x	4.18x	-
Interest Coverage	0.23x	-0.36x	0.54x	3.95x	6.27x	839.53x	1294.29x	11.32x	0.78x	-10.41x
Total Equity+	218.68M	200.63M	227.1M	425.58M	559.82M	1.33B	1.93B	4.93B	5.01B	2.98B
Equity Growth %	-0.11%	-0.08%	0.13%	0.87%	0.32%	1.38%	0.45%	1.56%	0.01%	-0.4%
Book Value per Share	6.41	6.13	6.73	10.00	12.99	30.57	45.00	85.97	74.94	44.41
Total Shareholders' Equity	218.68M	200.63M	227.1M	425.58M	559.82M	1.33B	1.93B	4.93B	5.01B	2.98B
Common Stock	33K	33K	35K	39K	42K	42K	0	0	100K	100K
Retained Earnings	9.55M	-4.25M	-12.42M	61.76M	134.68M	944.97M	1.65B	2.2B	2.19B	135.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-31K	-53K	0	-139K	-463K	-431K	400K	-67.6M	-30M	-36.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	36.31M	11.81M	27.71M	136.34M	134.49M	629.76M	805.87M	885.3M	280.2M	83M
Operating CF Margin %	0.19%	0.06%	0.1%	0.26%	0.25%	0.38%	0.47%	0.27%	0.09%	0.03%
Operating CF Growth %	0.02%	-0.67%	1.35%	3.92%	-0.01%	3.68%	0.28%	0.1%	-0.68%	-0.7%
Net Income	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.23M	548.7M	-10.1M	-2.05B
Depreciation & Amortization	23.39M	22.8M	30.76M	46.27M	47.83M	49.09M	54.38M	283.6M	457.2M	453.4M
Stock-Based Compensation	7.42M	7.99M	9.06M	11.71M	13.25M	21.02M	25.4M	48.4M	51.6M	42.1M
Deferred Taxes	-4.03M	-2.6M	365K	-20.46M	-1.74M	-20.21M	24.67M	0	0	-99.3M
Other Non-Cash Items	5M	4.99M	19.5M	26.98M	17.47M	20.65M	-34K	57.8M	-23.6M	1.9B
Working Capital Changes	10.61M	-7.54M	-23.81M	-2.33M	-15.24M	-251.07M	-2.78M	-53.2M	-194.9M	-158.7M
Change in Receivables	16.06M	-6.26M	-42.05M	8.24M	-36.06M	-402.09M	118.85M	150.2M	160M	5.4M
Change in Inventory	-1.64M	859K	362K	-3.97M	9.14M	-54.9M	-85.04M	-116.9M	-211.6M	-134.1M
Change in Payables	-3.08M	4.32M	12.96M	-331K	2.43M	52.23M	10.45M	23.5M	3M	-23.4M
Cash from Investing+	-17.03M	-16.97M	-431.76M	114.95M	-27.23M	-63.32M	-319.53M	-1.64B	-187.6M	-149.9M
Capital Expenditures	-17.03M	-11.91M	-17.51M	-31.69M	-27.23M	-64.93M	-292.72M	-140.9M	-209.3M	-195.1M
CapEx % of Revenue	0.09%	0.06%	0.06%	0.06%	0.05%	0.04%	0.17%	0.04%	0.07%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	146.64M	0	1.6M	36.88M	18.4M	3.5M	-10.7M
Cash from Financing+	-28.68M	-16.8M	270.61M	-244.06M	-98.28M	-130.28M	-173.18M	252M	-265.8M	48.8M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-723K	-207K	-9.18M	-54.82M	-59.51M	-48.04M	-76.99M	-46.3M	-43.8M	-9.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	19.28M	-94K	10.2M	104.66M	107.26M	564.84M	513.14M	744.4M	70.9M	-112.1M
FCF Margin %	0.1%	-0%	0.04%	0.2%	0.2%	0.34%	0.3%	0.23%	0.02%	-0.04%
FCF Growth %	-0.21%	-1%	109.5%	9.26%	0.02%	4.27%	-0.09%	0.45%	-0.9%	-2.58%
FCF per Share	0.57	-0.00	0.30	2.46	2.49	12.96	11.97	12.97	1.06	-1.67
FCF Conversion (FCF/Net Income)	-5.97x	-0.86x	-3.39x	1.84x	1.84x	0.78x	1.14x	1.61x	-27.74x	-0.04x
Interest Paid	7M	6.49M	9.14M	7.93M	2.29M	500K	0	95.1M	150M	177.5M
Taxes Paid	1.92M	490K	1.27M	6.92M	2.19M	109.91M	235.6M	264.8M	86.6M	177.5M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2.62%	-6.59%	-3.82%	22.73%	14.8%	85.63%	43.17%	15.99%	-0.2%	-51.36%
Return on Invested Capital (ROIC)	1.13%	-1.88%	1.87%	13.35%	12.54%	101.27%	61.29%	14.45%	1.39%	-22.51%
Gross Margin	63.45%	61.68%	56.22%	60.45%	59.98%	81.17%	75.26%	59.28%	49.85%	46.23%
Net Margin	-3.1%	-7.21%	-2.94%	14.2%	13.63%	48.76%	41.46%	16.8%	-0.34%	-73.74%
Debt / Equity	0.68x	0.74x	1.75x	0.25x	0.20x	0.08x	0.07x	0.58x	0.52x	0.90x
Interest Coverage	0.23x	-0.36x	0.54x	3.95x	6.27x	839.53x	1294.29x	11.32x	0.78x	-10.41x
FCF Conversion	-5.97x	-0.86x	-3.39x	1.84x	1.84x	0.78x	1.14x	1.61x	-27.74x	-0.04x
Revenue Growth	7.4%	-2.31%	44.96%	88.05%	2.41%	210.66%	2.22%	92.28%	-8.21%	-7.17%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other	-	-	-	-	-	-	-	302.7M	483.3M	-
Other Growth	-	-	-	-	-	-	-	-	59.66%	-
Immunoassays	-	121.42M	165.1M	183.16M	191.74M	1.14B	1.2B	-	-	-
Immunoassays Growth	-	-	35.98%	10.94%	4.68%	497.09%	4.60%	-	-	-
Cardiac Immunoassay	-	-	-	266.52M	266.5M	242.93M	255.79M	-	-	-
Cardiac Immunoassay Growth	-	-	-	-	-0.01%	-8.84%	5.29%	-	-	-
Molecular Diagnostic Solutions	-	-	-	19.36M	21.72M	222.96M	200.49M	-	-	-
Molecular Diagnostic Solutions Growth	-	-	-	-	12.18%	926.73%	-10.08%	-	-	-
Specialized Diagnostic Solutions	-	-	-	53.24M	54.93M	50.94M	44.82M	-	-	-
Specialized Diagnostic Solutions Growth	-	-	-	-	3.17%	-7.27%	-12.02%	-	-	-
Virology	-	40.08M	51.98M	-	-	-	-	-	-	-
Virology Growth	-	-	29.68%	-	-	-	-	-	-	-
Specialty products	-	9.39M	13.64M	-	-	-	-	-	-	-
Specialty products Growth	-	-	45.26%	-	-	-	-	-	-	-
Royalties, grants and other	-	11.21M	-	-	-	-	-	-	-	-
Royalties, grants and other Growth	-	-	-	-	-	-	-	-	-	-
Molecular	-	9.51M	-	-	-	-	-	-	-	-
Molecular Growth	-	-	-	-	-	-	-	-	-	-
Infectious Disease	141.86M	-	-	-	-	-	-	-	-	-
Infectious Disease Growth	-	-	-	-	-	-	-	-	-	-
Women Health	37.16M	-	-	-	-	-	-	-	-	-
Women Health Growth	-	-	-	-	-	-	-	-	-	-
Gastrointestinal Disease	7.22M	-	-	-	-	-	-	-	-	-
Gastrointestinal Disease Growth	-	-	-	-	-	-	-	-	-	-
License Fees And Royalties	6.19M	-	-	-	-	-	-	-	-	-
License Fees And Royalties Growth	-	-	-	-	-	-	-	-	-	-
Other Disease	3.7M	-	-	-	-	-	-	-	-	-
Other Disease Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	-	-	-	1.88B	1.62B
North America Growth	-	-	-	-	-	-	-	-	-	-13.71%
EMEA	-	-	-	-	-	-	-	-	327.3M	335.8M
EMEA Growth	-	-	-	-	-	-	-	-	-	2.60%
China	-	-	-	-	-	-	-	-	-	325M
China Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	483.3M	-
Other Growth	-	-	-	-	-	-	-	-	-	-
China	-	-	-	-	-	-	-	-	310.1M	-
China Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

QuidelOrtho Corporation (QDEL) reported $2.72B in revenue for fiscal year 2024. This represents a 1612% increase from $158.6M in 2011.

QuidelOrtho Corporation (QDEL) saw revenue decline by 7.2% over the past year.

QuidelOrtho Corporation (QDEL) reported a net loss of $1.18B for fiscal year 2024.

Dividend & Returns

QuidelOrtho Corporation (QDEL) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.

QuidelOrtho Corporation (QDEL) had negative free cash flow of $42.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

QuidelOrtho Corporation (QDEL) 10-Year Financial Performance & Capital Metrics

QDEL • • Industrial / General

HealthcareMedical InstrumentsDiagnostic & Monitoring EquipmentDiagnostic Testing & Monitoring

Revenue $2.78B -7.2%
EBITDA -$1.51B -352.8%
Net Income -$2.05B -20216.8%
EPS (Diluted) -30.54 -20260.0%
Gross Margin 46.23% -7.3%
EBITDA Margin -54.17% -372.3%
Operating Margin -70.46% -1618.6%
Net Margin -73.74% -21786.6%
ROE -51.36% -25176.4%
ROIC -22.51% -1717.1%
Debt/Equity 0.90 +72.0%
Interest Coverage -10.41 -1439.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 81 (top 19%)
✓Strong 5Y sales CAGR of 39.1%
✓Trading at only 0.8x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y31.31%

5Y39.07%

3Y17.89%

TTM-3.62%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM36.81%

EPS CAGR

10Y-

5Y-

3Y-

TTM39%

ROCE

10Y Avg15.74%

5Y Avg26.03%

3Y Avg-3.69%

Latest-29.81%

Peer Comparison

Diagnostic Testing & Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NNNNAnbio Biotechnology Class A Ordinary Shares	1.52B	34.59	617.68	21.95%	31.03%	29.08%	0.14%
DXRDaxor Corporation	69.03M	13.70	124.55	-93.84%	401.5%	9.78%	0.04%	0.02
BDXBecton, Dickinson and Company	59.36B	208.35	35.74	8.23%	7.68%	6.61%	4.5%	0.76
HOLXHologic, Inc.	16.73B	75.02	22.60	-0%	13.79%	11.5%	6.84%	0.52
GCTKGlucoTrack, Inc.	3.62M	3.98	0.07			-389.1%
QDELQuidelOrtho Corporation	2.4B	35.38	-1.16	-7.17%	-43.43%	-57.92%		0.90
KMTSKESTRA MEDICAL TECHNOLOGIES, LTD.	1.34B	22.98	-4.48	115.05%	-177.99%	-80.55%		0.22
OSUROraSure Technologies, Inc.	196.55M	2.74	-10.54	-54.17%	-47.92%	-16.64%	12%	0.04

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	196.13M	191.6M	277.74M	522.28M	534.89M	1.66B	1.7B	3.27B	3B	2.78B
Revenue Growth %	0.07%	-0.02%	0.45%	0.88%	0.02%	2.11%	0.02%	0.92%	-0.08%	-0.07%
Cost of Goods Sold+	71.69M	73.41M	121.6M	206.57M	214.09M	312.81M	420.3M	1.33B	1.5B	1.5B
COGS % of Revenue	0.37%	0.38%	0.44%	0.4%	0.4%	0.19%	0.25%	0.41%	0.5%	0.54%
Gross Profit+	124.44M	118.19M	156.14M	315.71M	320.81M	1.35B	1.28B	1.94B	1.49B	1.29B
Gross Margin %	0.63%	0.62%	0.56%	0.6%	0.6%	0.81%	0.75%	0.59%	0.5%	0.46%
Gross Profit Growth %	0.15%	-0.05%	0.32%	1.02%	0.02%	3.2%	-0.05%	0.51%	-0.23%	-0.14%
Operating Expenses+	121.7M	122.63M	130.08M	205.59M	228.09M	288.53M	372.3M	1.09B	1.36B	3.25B
OpEx % of Revenue	0.62%	0.64%	0.47%	0.39%	0.43%	0.17%	0.22%	0.33%	0.45%	1.17%
Selling, General & Admin	77.33M	74.88M	96.44M	153.94M	163.87M	200.54M	239.6M	621M	763.2M	766.8M
SG&A % of Revenue	0.39%	0.39%	0.35%	0.29%	0.31%	0.12%	0.14%	0.19%	0.25%	0.28%
Research & Development	35.51M	38.67M	33.64M	51.65M	52.55M	84.29M	95.7M	187.9M	246.8M	218.7M
R&D % of Revenue	0.18%	0.2%	0.12%	0.1%	0.1%	0.05%	0.06%	0.06%	0.08%	0.08%
Other Operating Expenses	8.86M	9.07M	0	0	11.67M	3.69M	37M	283.6M	345.3M	2.26B
Operating Income+	2.74M	-4.44M	9.55M	95.93M	92.72M	1.06B	906M	843.7M	139.1M	-1.96B
Operating Margin %	0.01%	-0.02%	0.03%	0.18%	0.17%	0.64%	0.53%	0.26%	0.05%	-0.7%
Operating Income Growth %	1.3%	-2.62%	3.15%	9.04%	-0.03%	10.44%	-0.15%	-0.07%	-0.84%	-15.1%
EBITDA+	11.59M	27.43M	40.31M	142.19M	140.54M	1.11B	958.7M	1.13B	596.3M	-1.51B
EBITDA Margin %	0.06%	0.14%	0.15%	0.27%	0.26%	0.67%	0.56%	0.35%	0.2%	-0.54%
EBITDA Growth %	31.51%	1.37%	0.47%	2.53%	-0.01%	6.89%	-0.14%	0.18%	-0.47%	-3.53%
D&A (Non-Cash Add-back)	8.86M	31.87M	30.76M	46.27M	47.83M	49.09M	52.7M	283.6M	457.2M	453.4M
EBIT	2.74M	-4.02M	9.55M	87.67M	91.97M	1.05B	900.6M	810.4M	149.8M	-1.94B
Net Interest Income+	-12.04M	-12.18M	-17.59M	-24.28M	-14.79M	-1.26M	-400K	-73.2M	-176.7M	-188.9M
Interest Income	0	0	0	0	0	0	300K	1.3M	2.2M	0
Interest Expense	12.04M	12.18M	17.59M	24.28M	14.79M	1.26M	700K	74.5M	178.9M	188.3M
Other Income/Expense	-12.04M	-11.76M	-17.59M	-32.55M	-15.54M	-20.01M	-5.7M	-107.8M	-168.2M	-170.6M
Pretax Income+	-9.3M	-16.2M	-8.04M	63.38M	77.18M	1.04B	900.3M	735.9M	-29.1M	-2.13B
Pretax Margin %	-0.05%	-0.08%	-0.03%	0.12%	0.14%	0.63%	0.53%	0.23%	-0.01%	-0.77%
Income Tax+	-3.22M	-2.39M	129K	-10.8M	4.26M	230.03M	196.1M	187.2M	-19M	-79.5M
Effective Tax Rate %	0.65%	0.85%	1.02%	1.17%	0.94%	0.78%	0.78%	0.75%	0.35%	0.96%
Net Income+	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.2M	548.7M	-10.1M	-2.05B
Net Margin %	-0.03%	-0.07%	-0.03%	0.14%	0.14%	0.49%	0.41%	0.17%	-0%	-0.74%
Net Income Growth %	0.14%	-1.27%	0.41%	10.09%	-0.02%	10.11%	-0.13%	-0.22%	-1.02%	-202.17%
Net Income (Continuing)	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.2M	548.7M	-10.1M	-2.05B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.18	-0.42	-0.24	1.74	1.73	18.60	16.43	9.56	-0.15	-30.54
EPS Growth %	0.14%	-1.33%	0.43%	8.25%	-0.01%	9.75%	-0.12%	-0.42%	-1.02%	-202.6%
EPS (Basic)	-0.18	-0.42	-0.24	1.74	1.78	19.24	16.74	9.66	-0.15	-30.54
Diluted Shares Outstanding	34.1M	32.71M	33.73M	42.55M	43.11M	43.59M	42.87M	57.4M	66.8M	67.2M
Basic Shares Outstanding	33.77M	32.71M	33.73M	42.55M	40.86M	42.12M	42.08M	56.8M	66.8M	67.2M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	240.66M	225.39M	331.23M	193.4M	222.23M	1.14B	1.44B	1.58B	1.31B	1.22B
Cash & Short-Term Investments	191.47M	169.51M	36.09M	43.7M	52.77M	489.94M	828.5M	345M	167.3M	98.3M
Cash Only	191.47M	169.51M	36.09M	43.7M	52.77M	489.94M	802.8M	292.9M	118.9M	98.3M
Short-Term Investments	0	0	0	0	0	0	25.7M	52.1M	48.4M	0
Accounts Receivable	18.4M	24.99M	78.36M	76.89M	102.35M	529.17M	393.8M	586.4M	488.4M	451.3M
Days Sales Outstanding	34.24	47.61	102.98	53.73	69.84	116.24	84.62	65.53	59.47	59.19
Inventory	26.39M	26.05M	67.08M	67.38M	58.09M	113.8M	198.8M	524.1M	577.8M	533.7M
Days Inventory Outstanding	134.35	129.49	201.34	119.05	99.03	132.78	172.64	143.85	140.28	130.18
Other Current Assets	63K	0	146.81M	928K	4.45M	2.16M	4.6M	22.9M	10M	58.3M
Total Non-Current Assets+	165.84M	162.86M	604.02M	612.97M	688.64M	728.76M	990.1M	7.28B	7.25B	5.2B
Property, Plant & Equipment	52.55M	50.86M	61.59M	73.9M	171.88M	211.03M	476.8M	1.52B	1.61B	1.55B
Fixed Asset Turnover	3.73x	3.77x	4.51x	7.07x	3.11x	7.87x	3.56x	2.15x	1.86x	1.80x
Goodwill	80.73M	83.83M	337.03M	337.02M	337.02M	337.03M	337M	2.48B	2.49B	649.5M
Intangible Assets	31.83M	27.64M	203.83M	175.03M	148.11M	122.43M	98.7M	3.12B	2.93B	2.74B
Long-Term Investments	0	0	0	0	0	0	37.9M	21M	7.4M	21.7M
Other Non-Current Assets	731K	525K	1.58M	4.83M	7.13M	13.51M	19.6M	122.7M	179.6M	249M
Total Assets+	406.5M	388.25M	935.25M	806.37M	910.87M	1.87B	2.43B	8.86B	8.56B	6.42B
Asset Turnover	0.48x	0.49x	0.30x	0.65x	0.59x	0.89x	0.70x	0.37x	0.35x	0.43x
Asset Growth %	-0.09%	-0.04%	1.41%	-0.14%	0.13%	1.05%	0.3%	2.64%	-0.03%	-0.25%
Total Current Liabilities+	30.83M	33.61M	128.35M	159.74M	125.89M	336.96M	323.5M	1.01B	833.8M	998.8M
Accounts Payable	8.68M	16.05M	27.28M	25.17M	26.7M	86.32M	101.5M	283.3M	294.8M	246M
Days Payables Outstanding	44.17	79.78	81.88	44.48	45.52	100.72	88.15	77.76	71.57	60
Short-Term Debt	0	0	20.18M	54.38M	12.66M	0	300K	207.5M	139.8M	341.8M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	336K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	8.08M	7.6M	64.52M	59.01M	62.49M	74.39M	65.5M	156.4M	127.8M	96.8M
Current Ratio	7.81x	6.71x	2.58x	1.21x	1.77x	3.39x	4.45x	1.56x	1.57x	1.22x
Quick Ratio	6.95x	5.93x	2.06x	0.79x	1.30x	3.05x	3.84x	1.04x	0.88x	0.69x
Cash Conversion Cycle	124.42	97.31	222.44	128.31	123.35	148.3	169.12	131.63	128.17	129.37
Total Non-Current Liabilities+	157M	154.01M	579.8M	221.05M	225.16M	201.5M	177.5M	2.91B	2.72B	2.44B
Long-Term Debt	143.3M	144.34M	377.26M	53.19M	0	0	400K	2.43B	2.27B	2.14B
Capital Lease Obligations	4.03M	3.98M	0	0	93.23M	100.71M	128.6M	186.4M	172.8M	167.2M
Deferred Tax Liabilities	1.97M	58K	430K	9.81M	30.02M	38.33M	0	213.2M	192.2M	76.5M
Other Non-Current Liabilities	7.7M	5.63M	202.11M	167.86M	131.93M	100.79M	48.5M	74.4M	83.6M	38M
Total Liabilities	187.83M	187.62M	708.15M	380.79M	351.05M	538.46M	501M	3.92B	3.56B	3.44B
Total Debt+	147.91M	148.42M	397.45M	107.57M	112.3M	108.5M	139.3M	2.85B	2.61B	2.68B
Net Debt	-43.56M	-21.09M	361.36M	63.87M	59.52M	-381.44M	-663.5M	2.56B	2.5B	2.58B
Debt / Equity	0.68x	0.74x	1.75x	0.25x	0.20x	0.08x	0.07x	0.58x	0.52x	0.90x
Debt / EBITDA	12.76x	5.41x	9.86x	0.76x	0.80x	0.10x	0.15x	2.53x	4.38x	-
Net Debt / EBITDA	-3.76x	-0.77x	8.96x	0.45x	0.42x	-0.34x	-0.69x	2.27x	4.18x	-
Interest Coverage	0.23x	-0.36x	0.54x	3.95x	6.27x	839.53x	1294.29x	11.32x	0.78x	-10.41x
Total Equity+	218.68M	200.63M	227.1M	425.58M	559.82M	1.33B	1.93B	4.93B	5.01B	2.98B
Equity Growth %	-0.11%	-0.08%	0.13%	0.87%	0.32%	1.38%	0.45%	1.56%	0.01%	-0.4%
Book Value per Share	6.41	6.13	6.73	10.00	12.99	30.57	45.00	85.97	74.94	44.41
Total Shareholders' Equity	218.68M	200.63M	227.1M	425.58M	559.82M	1.33B	1.93B	4.93B	5.01B	2.98B
Common Stock	33K	33K	35K	39K	42K	42K	0	0	100K	100K
Retained Earnings	9.55M	-4.25M	-12.42M	61.76M	134.68M	944.97M	1.65B	2.2B	2.19B	135.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-31K	-53K	0	-139K	-463K	-431K	400K	-67.6M	-30M	-36.2M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	36.31M	11.81M	27.71M	136.34M	134.49M	629.76M	805.87M	885.3M	280.2M	83M
Operating CF Margin %	0.19%	0.06%	0.1%	0.26%	0.25%	0.38%	0.47%	0.27%	0.09%	0.03%
Operating CF Growth %	0.02%	-0.67%	1.35%	3.92%	-0.01%	3.68%	0.28%	0.1%	-0.68%	-0.7%
Net Income	-6.08M	-13.81M	-8.16M	74.18M	72.92M	810.29M	704.23M	548.7M	-10.1M	-2.05B
Depreciation & Amortization	23.39M	22.8M	30.76M	46.27M	47.83M	49.09M	54.38M	283.6M	457.2M	453.4M
Stock-Based Compensation	7.42M	7.99M	9.06M	11.71M	13.25M	21.02M	25.4M	48.4M	51.6M	42.1M
Deferred Taxes	-4.03M	-2.6M	365K	-20.46M	-1.74M	-20.21M	24.67M	0	0	-99.3M
Other Non-Cash Items	5M	4.99M	19.5M	26.98M	17.47M	20.65M	-34K	57.8M	-23.6M	1.9B
Working Capital Changes	10.61M	-7.54M	-23.81M	-2.33M	-15.24M	-251.07M	-2.78M	-53.2M	-194.9M	-158.7M
Change in Receivables	16.06M	-6.26M	-42.05M	8.24M	-36.06M	-402.09M	118.85M	150.2M	160M	5.4M
Change in Inventory	-1.64M	859K	362K	-3.97M	9.14M	-54.9M	-85.04M	-116.9M	-211.6M	-134.1M
Change in Payables	-3.08M	4.32M	12.96M	-331K	2.43M	52.23M	10.45M	23.5M	3M	-23.4M
Cash from Investing+	-17.03M	-16.97M	-431.76M	114.95M	-27.23M	-63.32M	-319.53M	-1.64B	-187.6M	-149.9M
Capital Expenditures	-17.03M	-11.91M	-17.51M	-31.69M	-27.23M	-64.93M	-292.72M	-140.9M	-209.3M	-195.1M
CapEx % of Revenue	0.09%	0.06%	0.06%	0.06%	0.05%	0.04%	0.17%	0.04%	0.07%	0.07%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	146.64M	0	1.6M	36.88M	18.4M	3.5M	-10.7M
Cash from Financing+	-28.68M	-16.8M	270.61M	-244.06M	-98.28M	-130.28M	-173.18M	252M	-265.8M	48.8M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-723K	-207K	-9.18M	-54.82M	-59.51M	-48.04M	-76.99M	-46.3M	-43.8M	-9.6M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	19.28M	-94K	10.2M	104.66M	107.26M	564.84M	513.14M	744.4M	70.9M	-112.1M
FCF Margin %	0.1%	-0%	0.04%	0.2%	0.2%	0.34%	0.3%	0.23%	0.02%	-0.04%
FCF Growth %	-0.21%	-1%	109.5%	9.26%	0.02%	4.27%	-0.09%	0.45%	-0.9%	-2.58%
FCF per Share	0.57	-0.00	0.30	2.46	2.49	12.96	11.97	12.97	1.06	-1.67
FCF Conversion (FCF/Net Income)	-5.97x	-0.86x	-3.39x	1.84x	1.84x	0.78x	1.14x	1.61x	-27.74x	-0.04x
Interest Paid	7M	6.49M	9.14M	7.93M	2.29M	500K	0	95.1M	150M	177.5M
Taxes Paid	1.92M	490K	1.27M	6.92M	2.19M	109.91M	235.6M	264.8M	86.6M	177.5M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-2.62%	-6.59%	-3.82%	22.73%	14.8%	85.63%	43.17%	15.99%	-0.2%	-51.36%
Return on Invested Capital (ROIC)	1.13%	-1.88%	1.87%	13.35%	12.54%	101.27%	61.29%	14.45%	1.39%	-22.51%
Gross Margin	63.45%	61.68%	56.22%	60.45%	59.98%	81.17%	75.26%	59.28%	49.85%	46.23%
Net Margin	-3.1%	-7.21%	-2.94%	14.2%	13.63%	48.76%	41.46%	16.8%	-0.34%	-73.74%
Debt / Equity	0.68x	0.74x	1.75x	0.25x	0.20x	0.08x	0.07x	0.58x	0.52x	0.90x
Interest Coverage	0.23x	-0.36x	0.54x	3.95x	6.27x	839.53x	1294.29x	11.32x	0.78x	-10.41x
FCF Conversion	-5.97x	-0.86x	-3.39x	1.84x	1.84x	0.78x	1.14x	1.61x	-27.74x	-0.04x
Revenue Growth	7.4%	-2.31%	44.96%	88.05%	2.41%	210.66%	2.22%	92.28%	-8.21%	-7.17%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Other	-	-	-	-	-	-	-	302.7M	483.3M	-
Other Growth	-	-	-	-	-	-	-	-	59.66%	-
Immunoassays	-	121.42M	165.1M	183.16M	191.74M	1.14B	1.2B	-	-	-
Immunoassays Growth	-	-	35.98%	10.94%	4.68%	497.09%	4.60%	-	-	-
Cardiac Immunoassay	-	-	-	266.52M	266.5M	242.93M	255.79M	-	-	-
Cardiac Immunoassay Growth	-	-	-	-	-0.01%	-8.84%	5.29%	-	-	-
Molecular Diagnostic Solutions	-	-	-	19.36M	21.72M	222.96M	200.49M	-	-	-
Molecular Diagnostic Solutions Growth	-	-	-	-	12.18%	926.73%	-10.08%	-	-	-
Specialized Diagnostic Solutions	-	-	-	53.24M	54.93M	50.94M	44.82M	-	-	-
Specialized Diagnostic Solutions Growth	-	-	-	-	3.17%	-7.27%	-12.02%	-	-	-
Virology	-	40.08M	51.98M	-	-	-	-	-	-	-
Virology Growth	-	-	29.68%	-	-	-	-	-	-	-
Specialty products	-	9.39M	13.64M	-	-	-	-	-	-	-
Specialty products Growth	-	-	45.26%	-	-	-	-	-	-	-
Royalties, grants and other	-	11.21M	-	-	-	-	-	-	-	-
Royalties, grants and other Growth	-	-	-	-	-	-	-	-	-	-
Molecular	-	9.51M	-	-	-	-	-	-	-	-
Molecular Growth	-	-	-	-	-	-	-	-	-	-
Infectious Disease	141.86M	-	-	-	-	-	-	-	-	-
Infectious Disease Growth	-	-	-	-	-	-	-	-	-	-
Women Health	37.16M	-	-	-	-	-	-	-	-	-
Women Health Growth	-	-	-	-	-	-	-	-	-	-
Gastrointestinal Disease	7.22M	-	-	-	-	-	-	-	-	-
Gastrointestinal Disease Growth	-	-	-	-	-	-	-	-	-	-
License Fees And Royalties	6.19M	-	-	-	-	-	-	-	-	-
License Fees And Royalties Growth	-	-	-	-	-	-	-	-	-	-
Other Disease	3.7M	-	-	-	-	-	-	-	-	-
Other Disease Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
North America	-	-	-	-	-	-	-	-	1.88B	1.62B
North America Growth	-	-	-	-	-	-	-	-	-	-13.71%
EMEA	-	-	-	-	-	-	-	-	327.3M	335.8M
EMEA Growth	-	-	-	-	-	-	-	-	-	2.60%
China	-	-	-	-	-	-	-	-	-	325M
China Growth	-	-	-	-	-	-	-	-	-	-
Other	-	-	-	-	-	-	-	-	483.3M	-
Other Growth	-	-	-	-	-	-	-	-	-	-
China	-	-	-	-	-	-	-	-	310.1M	-
China Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

QuidelOrtho Corporation (QDEL) reported $2.72B in revenue for fiscal year 2024. This represents a 1612% increase from $158.6M in 2011.

QuidelOrtho Corporation (QDEL) saw revenue decline by 7.2% over the past year.

QuidelOrtho Corporation (QDEL) reported a net loss of $1.18B for fiscal year 2024.

Dividend & Returns

QuidelOrtho Corporation (QDEL) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.

QuidelOrtho Corporation (QDEL) had negative free cash flow of $42.8M in fiscal year 2024, likely due to heavy capital investments.